Abstract
Purpose. To evaluate the use of carrier-based dry powder aerosols for inhalation delivery of proteins and examine the effect of fine particle excipients as potential formulation performance modifiers.
Methods. Bovine serum albumin (BSA) was co-processed with malto-dextrin by spray-drying to produce model protein particles. Aerosol formulations were prepared by tumble mixing protein powders with α-lactose monohydrate (63−90 μm) or modified lactoses containing between 2.5 and 10% w/w fine particle lactose (FPL) or micronised polyethylene glycol 6000. Powder blends were characterised in terms of particle size distribution, morphology and powder flow. Formulation performance in Diskhaler® and Rotahaler® devices was investigated using a twin stage impinger operating at 60 1 min−1.
Results. Inhalation performance of binary ordered mixes prepared using BSA-maltodextrin and lactose (63−90 μm) was improved by addition of FPL and micronised PEG 6000. For the addition of 5% w/w FPL the protein fine particle fraction (0.5−6.4 μm) using the Diskhaler® was increased from 31.7 ± 2.4% to 47.4 ± 2.2%. Inclusion of FPL and micronised PEG 6000 changed the bulk properties of inhalation powders and reduced powder flow but did not affect device emptying. Unexpectedly, improvements in performance were found to be independent of the order of addition of FPL to the ternary powder formulations. SEM studies revealed that this was probably the result of a redistribution of protein particles between the coarse carrier lactose component and added FPL during mixing.
Conclusions. Fine particle excipients can be used to improve the performance of carrier-based protein dry powder aerosols. Mechanistically, enhancement of performance is proposed to result from a redistribution of protein particles from coarse carrier particles to the fine particle component in the ternary mix.
Similar content being viewed by others
REFERENCES
I. Gonda, D. C. Cipolla, S. J. Shire, K. Meserve, S. Weck, A. R. Clark, and H-K. Chan. A case study in aerosol protein drug development: aqueous solution aerosols of rhDNase. In P. R. Byron, R. N. Dalby, and S. J. Farr (eds.), Respiratory drug delivery IV, Interpharm Press Inc., Buffalo Grove, IL, 1994, pp. 47–54.
A. Gillissen, J. H. Roum, R. F. Hoyt, and R. G. Crystal. Aerosolization of superoxide dismutase. Augmentation of respiratory lining fluid antioxidant screen by aerosolization of recombinant human Cu++/Zn++ superoxide dismutase. Chest 104:811–815 (1993).
H-K. Chan, A. Clark, I. Gonda, M. Mumenthaler, and C. Hsu. Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery. Pharm. Res. 14:431–437 (1997).
R. W. Niven, F. D. Lott, A. Y. Ip, and J. M. Cribbs. Pulmonary delivery of powders and solutions containing recombinant human granulocyte colony-stimulating factor (rhG-CSF) to the rabbit. Pharm. Res. 11:1101–1109 (1994).
A. Adjei and J. Garren. Pulmonary delivery of peptide drugs: Effect of particle size on bioavailability of leuprolide acetate in healthy male volunteers. Pharm. Res. 7:565–569 (1990).
R. W. Niven, A. Y. Ip, S. D. Mittelman, C. Farrar, T. Arakawa, and S. J. Prestrelski. Protein nebulization: I. Stability of lactate dehydrogenase and recombinant granulocyte-colony stimulating factor to air-jet nebulization. Int. J. Pharm. 109:17–26 (1994).
J. Broadhead, S. K. Edmond Rouan, and C. T. Rhodes. The deposition of spray-dried β-galactosidase from dry powder inhaler devices. Drug Dev. Ind. Pharm. 22:813–822 (1996).
M. Mumenthaler, C. C. Hsu, and R. Pearlman. Feasibility study on spray-drying protein pharmaceuticals: Recombinant growth hormone and tissue-type plasminogen activator. Pharm. Res. 11:12–20 (1994).
A. J. Hickey. Lung deposition and clearance of pharmaceutical aerosols: What can be learned from inhalation toxicology and industrial hygiene? Aerosol Sci. Tech. 18:290–304 (1993).
P. R. Byron. Some future perspectives for unit dose inhalation aerosols. Drug Dev. Ind. Pharm. 12:993–1015 (1986).
J. A. Hersey. Ordered Mixing: A new concept in powder mixing practice. Powder Technol. 11:41–44 (1975).
J. S. Patton and R. M. Platz. Penetration enhancement for polypeptides through epithelia. (D) Routes of delivery: Case studies (2) Pulmonary delivery of peptides and proteins for systemic action. Adv. Drug Del. Rev. 8:179–196 (1992).
N. M. Kassem and D. Ganderton. The influence of carrier surface on the characteristics of inspirable powder aerosols. J. Pharm. Pharmacol. 42(Suppl):11P (1990).
D. Ganderton. The generation of respirable clouds from coarse powder aggregates. J. Biopharm. Sci. 3:101–105 (1992).
J. D. Lord and J. N. Staniforth. Particle size effects on packing and dispersion of powders. In R. N. Dalby, P. R. Byron, and S. J. Farr (eds.), Respiratory drug delivery V, Interpharm Press Inc., Buffalo Grove, IL, 1996, pp. 75–84.
P. Cook and J. A. Hersey. Powder mixing in the tableting of fenfluramine hydrochloride; evaluation of a mixer. J. Pharm. Pharmacol. 26:298–303 (1974).
M. J. Crooks and R. Ho. Ordered mixing in direct compression of tablets. Powder Technol. 14:161–167 (1976).
R. L. Carr. Evaluating flow properties of solids. Chem. Eng. 72:163–168 (1965).
G. W. Hallworth and D. G. Westmoreland. The twin impinger: a simple device for assessing the delivery of drugs from metered dose pressurized aerosol inhalers. J. Pharm. Pharmacol. 39:966–972 (1987).
D. L. French, D. A. Edwards, and R. W. Niven. The influence of formulation on emission, deaggregation and deposition of dry powders for inhalation. J. Aerosol Sci. 27:769–783 (1996).
J. N. Staniforth. Performance-modifying influences in dry powder inhalation systems. Aerosol. Sci. Tech. 22:346–353 (1995).
A. H. de Boer, D. Gjaltema, and P. Hagedoorn. Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers Part 2: Effect of peak flow rate (PIFR) and inspiration time on the in vitro drug release from three different types of commercial dry powder inhalers. Int. J. Pharm. 138:45–56 (1996).
B. J. Meakin, J. M. Cainey, and P. M. Woodcock. Drug delivery characteristics of Bricanyl Turbohaler™ dry powder inhalers. Int. J. Pharm. 119:91–102 (1995).
S. S. Soebagyo and P. J. Stewart. The effect of cohesive and noncohesive ternary components on the homogeneity and stability of a prednisolone interactive mixture. Int. J. Pharm. 25:225–236 (1985).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lucas, P., Anderson, K. & Staniforth, J.N. Protein Deposition from Dry Powder Inhalers: Fine Particle Multiplets as Performance Modifiers. Pharm Res 15, 562–569 (1998). https://doi.org/10.1023/A:1011977826711
Issue Date:
DOI: https://doi.org/10.1023/A:1011977826711